Vimarsana
Biggest News Aggregation in the World

Page 20 - Drug Controller General News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Controller General. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Controller General Today - Breaking & Trending Today

Saving India's 'Global Pharmacy' Image & Shaping 'e-Pharmacies': New Health Secy's Challenges Ahead - Vimarsana News

Saving India's 'Global Pharmacy' Image & Shaping 'e-Pharmacies': New Health Secy's Challenges Ahead

Meeting the deadline for the elimination of tuberculosis by 2025 --- five years ahead of the global deadline as promised by PM Modi --- and checking the progress of lagging targets fixed by India's National Health Policy are among Sudhansh Pant’s battles ahead

Source: news18.com
Groundbreaking Business Idea: Invest Rs 2 Lakh, Earn Rs 75K To Rs 1 Lakh Returns - Vimarsana News

Groundbreaking Business Idea: Invest Rs 2 Lakh, Earn Rs 75K To Rs 1 Lakh Returns

Manufacturing sanitary napkins is a lucrative industry with high demand. It is a hygiene item that many ladies use all throughout the world. 

Source: india.com
Akums gets DCGI nod for triple combination diabetes medication - Vimarsana News

Akums gets DCGI nod for triple combination diabetes medication

Akums Drugs and Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) for a triple combination diabetes medication. The drug combines Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500 to provide better treatment without the need for multiple drugs.

Drug firms move ministry over FDC ban, seek time to sell stock - Vimarsana News

Drug firms move ministry over FDC ban, seek time to sell stock

FDC drugs, which contain a combination of two or more active pharmaceutical ingredients (APIs) in a fixed ratio, were recently baned by Drug Controller General of India (DCGI).

A WHO alert about Indian pharma firm failed to spark strong regulatory action, experts say - Vimarsana News

A WHO alert about Indian pharma firm failed to spark strong regulatory action, experts say

Officials say since the eye ointment it made did not cause a serious adverse event, strict action was not warranted. Experts disagree.

Source: scroll.in